Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors

Leuk Lymphoma. 2020 Feb;61(2):473-476. doi: 10.1080/10428194.2019.1668937. Epub 2019 Sep 30.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Mutation

Substances

  • Isocitrate Dehydrogenase
  • IDH1 protein, human